ArticleMolecular and cellular biochemistry2023
Novel artificial intelligent transformer U-NET for better identification and management of prostate cancer.
Article in Molecular and cellular biochemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- AI-based detection of MRI-invisible prostate cancer with nnU-Net.The Canadian journal of urology · 2025Article
- Generative Artificial Intelligence in Prostate Cancer Imaging.Balkan medical journal · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Advancements in artificial intelligence (AI) strengthens life-altering technology that can not only reduce human workload but also enhance speed and efficiency in medicine. Medical image segmentation, for example, MRI analysis, is an arduous task for humans that AI can accomplish efficiently. AI in medical sciences have been studied; however, current literature is deficient of state-of-the-art development in computer vision, hence, advances are needed to be addressed. In this article, we provided a novel U-net architecture which utilizes transformers, convolution neural networks (CNNs) and medical information to depict the impact of AI in medicine and cancer. This model was tested on the PROMISE-12 dataset, a complete dataset of prostate cancer MRI images, where the architecture was compared with other conventional deep learning models to evaluate its performance. Dice similarity coefficient (DSC) and loss values were used as a metric of the predicted image segmentation by the three architectures. Our data support the hypothesis that Transformer-based U-Net architecture is superior when compared to conventional AI architectures for prostate cancer MRI scans. This novel Transformer-based U-Net architecture contributes to the advancement of prostate cancer segmentation and has a future in cancer diagnosis.
Indexed as
Identifiers
36350463What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.